Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Angeion Reports Decrease In Revenues
Angeion has posted a revenue of $6.2m for the first quarter of 2009, compared to $7.5m for the same period of 2008. The operating income for the company
Angeion has posted a revenue of $6.2m for the first quarter of 2009, compared to $7.5m for the same period of 2008. The operating income for the company
Provectus has added Mount Sinai School of Medicine as its second and final site for its expanded phase 2 clinical trial of dermatology agent PH-10 for psoriasis. Jason
Bristol-Myers Squibb has reported that clinical data added to the labeling for Orencia (abatacept) support use of Orencia for patients with moderate to severe rheumatoid arthritis of less
The FDA has reminded the public that stolen vials of the long-acting insulin Levemir made by Novo Nordisk still may be on the market. Reportedly, evidence gathered to
According to Endo Pharmaceuticals (Endo), Fortesta is a patented 2% testosterone transdermal gel for testosterone replacement therapy in male hypogonadism. It utilizes a metered dose delivery system designed
As per lawsuit, Abbott has willfully undertaken and carried out the aforesaid infringing activity with knowledge of” the patent. Previously, Bruce Saffran has won a patent infringement suit
Switzerland-based plasma products manufacturer, Octapharma is guiding an international initiative focused on confronting the risk associated with hemophilia A therapy – anti-factor VIII (FVIII) antibodies, also known as
Dainippon Sumitomo Pharma has reported positive results from PEARL 2, a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In the trial, both
Nutra Pharma has completed a licensing agreement that grants XenaCare ongoing exclusive US marketing and distribution rights for Cobroxin. Cobroxin is an OTC pain reliever clinically proven to
Lakewood-Amedex has announced that it is accelerating development of its broad spectrum anti-influenza product into clinical studies. Lakewood-Amedex’s (L-A) nRNA product is said to work by selectively silencing